Oxford Finance delivered a credit facility to lateral flow diagnostics developer DCN Dx while also arranging an equity investment for the company by Martis Capital, a private equity firm focused on the healthcare industry.
“DCN Dx is a recognized leader in outsourced lateral flow assay development with deep knowledge of the space,” Tracy S. Maziek, head of healthcare services at Oxford Finance, said. “Oxford is proud to support the company’s mission in creating rapid diagnostic solutions for an array of point-of-care applications, including infectious diseases, which is critical during these challenging times.”
“DCN Dx has established a track record of success by consistently solving its clients’ problems,” Charlie Mamrak, future CEO of DCN Dx, said. “I am excited to leverage the team’s deep scientific expertise to advance and expand the company’s capabilities into the future alongside our new capital partners.”
“DCN Dx is at the forefront of an exciting transformation in point-of-care diagnostics,” Owen Davis, partner at Martis Capital, said. “Oxford’s partnership approach to the transaction and flexible capital solution will enable the company to accelerate its growth.”
Oxford Finance is a specialty finance firm providing senior secured loans to public and private life sciences and healthcare services companies.
